Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer

Abiraterone Acetate ◽

Androgen Deprivation ◽

Benefit Of Abiraterone Acetate Plus Prednisone (AA+P) Added To Androgen Deprivation Therapy (ADT) In Patients With High-Risk, Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): Post Hoc Analysis Of EQ-5D-5L From The Latitude Study

Value in Health ◽

10.1016/j.jval.2018.04.317 ◽

2018 ◽

Vol 21 ◽

pp. S38 ◽

Cited By ~ 1

Author(s):

H Metin ◽

K McQuarrie ◽

P Thilakarathne ◽

J Diels ◽

T Ito ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Newly Diagnosed ◽

Post Hoc Analysis ◽

Hormone Sensitive ◽

Post Hoc

Faculty Opinions recommendation of Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732006685.793538242 ◽

2017 ◽

Author(s):

Michael Glode

Keyword(s):

Prostate Cancer ◽

Systematic Review ◽

High Risk ◽

Meta Analysis ◽

Abiraterone Acetate ◽

Androgen Deprivation

What are the effects of abiraterone acetate as adjunct to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer?

Cochrane Clinical Answers ◽

10.1002/cca.3570 ◽

2021 ◽

Author(s):

Sera Tort ◽

Marta Briarava

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Re: Intense Androgen-Deprivation Therapy with Abiraterone Acetate plus Leuprolide Acetate in Patients with Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study

The Journal of Urology ◽

10.1016/j.juro.2015.03.046 ◽

2015 ◽

Vol 193 (6) ◽

pp. 1983-1983

Author(s):

Samir S. Taneja

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Phase Ii ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Leuprolide Acetate ◽

High Risk Prostate Cancer ◽

Randomized Phase Ii ◽

Risk Prostate Cancer

Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476)

Annals of Oncology ◽

10.1093/annonc/mdx440.024 ◽

2017 ◽

Vol 28 ◽

pp. v619 ◽

Cited By ~ 7

Author(s):

M.R. Sydes ◽

M.D. Mason ◽

M.R. Spears ◽

N.W. Clarke ◽

D. Dearnaley ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

High Risk Prostate Cancer ◽

Risk Prostate Cancer

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2017.12.012 ◽

2018 ◽

Vol 16 (2) ◽

pp. 130-134 ◽

Cited By ~ 8

Author(s):

Edoardo Francini ◽

Steven Yip ◽

Shubidito Ahmed ◽

Haocheng Li ◽

Luke Ardolino ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Outcomes ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Castration Resistant ◽

Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer (mHSPC): An updated network meta-analysis and cost minimization analysis in China.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e17008 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e17008-e17008

Author(s):

Xin Hu ◽

Xingxing Yao ◽

Chaoyun Li ◽

Yanjun Liu ◽

Tengbin Xiong ◽

...

Keyword(s):

Prostate Cancer ◽

Cost Minimization ◽

Meta Analysis ◽

High Volume ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Cost Minimization Analysis ◽

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd013245.pub2 ◽

2020 ◽

Author(s):

Niranjan J Sathianathen ◽

Makinna C Oestreich ◽

Sarah Jane Brown ◽

Shilpa Gupta ◽

Badrinath R Konety ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial

European Urology ◽

10.1016/j.eururo.2021.06.023 ◽

2021 ◽

Author(s):

Gerhardt Attard ◽

Louise C. Brown ◽

Noel W. Clarke ◽

Mahesh K.B. Parmar ◽

Nicholas D. James

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Advanced Prostate Cancer ◽

Locally Advanced ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Locally Advanced Prostate Cancer

Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis

European Urology ◽

10.1016/j.eururo.2017.10.002 ◽

2018 ◽

Vol 73 (6) ◽

pp. 834-844 ◽

Cited By ~ 37

Author(s):

Christopher J.D. Wallis ◽

Zachary Klaassen ◽

Bimal Bhindi ◽

Hanan Goldberg ◽

Thenappan Chandrasekar ◽

...

Keyword(s):

Prostate Cancer ◽

Systematic Review ◽

High Risk ◽

Meta Analysis ◽

Abiraterone Acetate ◽

Androgen Deprivation